Journal of Comparative Effectiveness Research

Papers
(The H4-Index of Journal of Comparative Effectiveness Research is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more198
Access in all areas? A round-up of developments in market access and health technology assessment: part 1047
Journal of Comparative Effectiveness Research : 2022 year in review46
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy38
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis32
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary29
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis29
Engaging veterans in the research process: a practical guide29
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea24
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis24
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis22
Corrigendum21
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database21
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study20
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis19
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies19
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 2017
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults17
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims17
Cost–effectiveness analysis of a resource-intensive approach versus minimally invasive strategy for high-risk transcatheter aortic valve replacement patients17
0.11625814437866